Valeant Pharmaceuticals International Inc. said it was refinancing some of its existing debt.
The company plans to borrow $3.82 billion in new term B loans that replace its current credit agreements.
The Canadian drugmaker said the new credit agreement will modify the covenants, lower the interest rates and add its unit Valeant Pharmaceuticals International as a co-borrower.
The company's unit may also issue $750 million of secured debt securities and $750 million of unsecured debt securities.
Valeant, which is renaming itself as Bausch Health Companies Inc., said the new loan will also be used to redeem certain senior notes.
The senior notes to be redeemed include the 5.375% senior notes due 2020, 6.375% senior notes due 2020, 6.75% senior notes due 2021 and 7.25% senior notes due 2022.